Now I have all the information needed. Let me produce the final consolidated review.

## Summary

This paper presents TrASPr, a multi-Transformer model for tissue-specific splicing prediction, and BOS, a Bayesian optimization framework for splicing sequence design. TrASPr centers four separate pre-trained Transformers on the four splice sites of a cassette exon, combines their representations with genomic features, and is trained on genome-wide data from human and mouse. BOS uses TrASPr as an oracle within a latent-space Bayesian optimization loop to generate sequences with desired splicing outcomes under edit-distance constraints. The paper evaluates TrASPr on GTEx PSI prediction, MGP dPSI prediction, ENCODE RBP knockdown data, and a Daam1 mini-gene reporter assay, and benchmarks BOS against random mutation and a genetic algorithm baseline.

## Strengths

- **Novel, well-motivated architecture**: The multi-Transformer design focused on the four splice sites of cassette exons is a principled response to the problem that regulatory elements are concentrated near splice sites while full cassette-exon regions can span many kilobases. This architectural choice avoids the need for impractically large sequence windows.

- **Domain-specific pre-training outperforms general genomic models**: TrASPr's BERT model pre-trained on 1.5M splice-site-centered sequences outperforms the larger DNABERT (pre-trained on the full human genome) on the splicing prediction task (Section 4.2). This provides concrete evidence that task-specific pre-training on relevant sequence regions is more beneficial than generic genomic pre-training.

- **Independent biological validation**: TrASPr correctly predicts the direction of splicing change for 7/9 mutations in the Daam1 mini-gene reporter assay (p=0.0012, Figure 5a) and for >50% of cases in ENCODE RBP knockdown experiments (p=0.0001, Figure 4c). These are out-of-distribution tests on independent experimental data, providing genuine evidence that the model captures real regulatory mechanisms beyond dataset-specific correlations.

- **Comprehensive ablation study**: The ablation isolates the contributions of pre-training (noPre), features (noFeat), and transformer architecture (wLSTM vs. noFeat), showing each component provides measurable benefit (Table 2). This gives confidence that the design choices are substantiated.

- **Novel BOS framework for splicing design**: Formulating splicing sequence design as a constrained Bayesian optimization problem with a VAE-based latent space and Levenshtein constraints is novel for this domain. The framework is clearly described and compared against appropriate baselines (random mutation, genetic algorithm from Sample et al.).

## Weaknesses

### Fatal
None.

### Major

- **Pangolin comparison may overstate the improvement gap**. Pangolin is evaluated by feeding it the 3' and 5' splice sites and averaging the two predictions — a protocol it was not designed for, since Pangolin is a sliding-window model that predicts usage for a central position and was trained on different species/tissues. The reported Pearson correlation of 0.17 is near-chance for a continuous outcome, and the paper does not clarify whether Pangolin was retrained on the same data or used as a pre-trained model off-the-shelf. The resulting 64-point gap (0.81 vs. 0.17) is so large that, without a controlled comparison (identical train/test splits, shared evaluation pipeline, retraining), the headline claim that TrASPr achieves "state-of-the-art" PSI prediction over sequence-based models is not reliably substantiated. The paper's discussion offers possible explanations (e.g., window size mismatch, condition-specific regulation) but does not perform diagnostic analysis to differentiate among them.

- **dPSI evaluation on MGP data shows evidence of train/test leakage that is not adequately addressed**. The paper reports that under a "more stringent filtering" of the test set, TrASPr's performance degrades while the AE+MLP baseline improves (Section 4.1). The authors attribute this to TrASPr benefiting from training examples whose labels correlate with similar test examples — a textbook sign of leakage. Yet the primary results in Table 1 and Figure 3 are presented on the unfiltered (standard) split, and the filtered results are mentioned only in a single sentence without quantitative reporting. This presentation gives a misleading impression of TrASPr's advantage. The paper should report filtered results as primary, or at minimum provide a side-by-side comparison with the filtered numbers alongside the standard ones. The current framing inflates the claimed improvement.

### Minor

- **BOS evaluation is partially circular and its biological claims are overstated**. The paper explicitly states "we assume the Oracle is correct and only assess the ability to efficiently generate candidate sequences" (Section 4.4), which appropriately acknowledges the circularity in the efficiency comparison (30.3% vs. 4.0%/4.7%). However, the subsequent language — "15 cases where the known RBP regulatory motifs were mutated to increase inclusion," "BOS frequently mutated the validated regulatory regions" — implies biological discovery, when in fact these are computational predictions from the same TrASPr oracle being optimized. The BOS contribution is a solid computational proof-of-concept for an optimization framework; the paper would benefit from more carefully calibrating the language to match this framing.

- **VAE training details for BOS are underspecified**. The paper states the VAE uses a 6-layer Transformer encoder and decoder, but does not specify latent dimensionality, training loss (e.g., ELBO details, β parameter), reconstruction accuracy, data used for training, batch size, or sequence-length handling. Since BOS relies on the VAE to map between discrete sequences and a continuous latent space, reproducibility of the BOS results is limited without these details.

- **The "standard" vs. "stringent" filter criteria are not defined**. The paper mentions "two levels of filters" for the MGP test set but never specifies what the stringent filter removes (e.g., sequence identity thresholds, overlap criteria, number of remaining test examples). This is critical for assessing the leakage concern.

### Trivial

- None.

## Nice-to-Haves

- For the Pangolin comparison, retraining both models on identical train/test splits of GTEx with the same evaluation pipeline (including per-tissue correlations with confidence intervals) would turn the comparison from a potential artifact into a clean scientific finding.
- For the dPSI leakage, reporting the filtered results as the primary evaluation and transparently stating the number of test examples removed would eliminate the concern.
- For BOS, an additional validation step that does not depend on the oracle — e.g., testing BOS-generated mutations against held-out ENCODE KD data or published minigene results — would significantly strengthen the design contribution.
- Confidence intervals or error bars would strengthen several reported results (e.g., Figure 6 success rates, per-tissue correlations).

## Removed Points

*Critic's claim that wLSTM is a "double ablation" making it an unfair comparison* — Removed. The ablation design cleanly isolates pre-training (TrASPr vs. noPre), features (TrASPr vs. noFeat), and architecture (noFeat vs. wLSTM: both lack features, so the difference isolates the Transformer vs. LSTM comparison, even though wLSTM lacks pre-training while noFeat has it). The pattern of results supports the paper's architectural conclusions regardless.

*Critic's complaint about the 400bp window limitation and long-range regulation* — Removed. The paper explicitly motivates this choice by citing biological literature on RBP binding proximity ("RBPs typically bind up to a few hundred bases away") and discusses the challenge of long regions in the introduction.

*Critic's assertion that the paper does not discuss Pangolin comparison fairness* — Partially removed. The paper does discuss potential reasons for Pangolin's poor performance (window size, condition-specific regulation, confounding splice signals). What remains in the Weaknesses section is the substantiated concern about the comparison protocol itself, not a lack of discussion.

*Critic's general reproducibility nitpicks about undisclosed hyperparameters* — Removed where they concern minor implementation details (training time, GPU requirements). Only the substantive VAE underspecification concern is retained.

*Generic speculative concerns (e.g., "could Pangolin be uncalibrated for the tissues used?")* — Removed; these are unsupported speculation.

## Novel Insights

The most interesting observation emerging from the cross-referencing of strengths and weaknesses is that TrASPr's independent validation (Daam1 mini-gene: 7/9 correct, ENCODE KD: >50% correct direction, p=0.0001) is arguably its strongest evidence, yet this validation is largely decoupled from the contested comparisons (Pangolin, dPSI leakage). This suggests the paper's core contribution — that a multi-Transformer architecture with splice-site pre-training captures biologically meaningful regulatory logic — rests on firmer ground than the SOTA comparison claims. Conversely, the systematic failure pattern (both Daam1 and ENCODE KD show the model correctly predicts increased-inclusion events but misses decreased-inclusion events, particularly for region 11 in Daam1) hints at a genuine limitation worth investigating: the model may be biased toward predicting inclusion-promoting regulatory effects, possibly because the training data has more examples of constitutive or high-inclusion exons. This asymmetry is more interesting than most of the debated evaluation details.

## Suggestions

1. **Conduct a controlled comparison on the PSI prediction task**: Retrain Pangolin (or adopt an equivalent protocol) on identical GTEx train/test splits with shared preprocessing, and report per-tissue correlations with confidence intervals. If the gap persists, perform diagnostic analysis (e.g., does Pangolin fail on long introns, specific sequence features, or particular tissues?). This would either substantiate the SOTA claim or reveal where the gap comes from.

2. **Present dPSI results transparently**: Report both the standard and stringent-filtered results side-by-side (e.g., in Table 1). State clearly how many test examples are removed under each filter and whether TrASPr still outperforms AE+MLP on the filtered set. If it does not, state this limitation directly.

3. **Specify the VAE architecture in full**: Report latent dimensionality, training loss (ELBO with β parameter), reconstruction accuracy, data composition, batch size, and how sequences of varying lengths are handled. This is necessary for reproducibility of BOS.

4. **Calibrate language around BOS**: Replace phrasing that implies biological discovery with language that clearly frames BOS as a computational optimization framework. The known-motif analysis (15 cases) is an interesting sanity check but should be presented as such, not as independent validation.

5. **Investigate the decreased-inclusion failure mode**: The model's systematic difficulty with predicting decreased-inclusion events (both in ENCODE KD ~50% misses and Daam1 region 11) merits analysis and discussion. A hypothesis about training label imbalance or the model's learned prior would strengthen the paper.

## Score and Decision

This paper tackles an important problem with a well-motivated architectural contribution (multi-Transformer with splice-site pre-training) and a novel extension to sequence design (BOS). The model shows genuine promise through independent biological validation (Daam1, ENCODE KD) and thorough ablation studies. However, the evaluation of the headline prediction claims is weakened by two issues: a Pangolin comparison using a mismatched evaluation protocol, and evidence of train/test leakage in the dPSI results that is reported but not adequately addressed. Neither issue is fatal — they undercut the precision of the claimed improvements, not the validity of the approach — but they prevent the paper from making a fully convincing case for state-of-the-art performance. The paper's core ideas (domain-specific splice-site transformers, LSBO for splicing design) are valuable and deserve acceptance with requested revisions to tighten the evaluation.

MY FINAL SCORE: <score>6.0</score>
MY FINAL DECISION: <decision>Accept</decision>